Sign in
Stories
Cue Biopharma to Present Corporate Update at Healthcare Conference
Share
4D Molecular Therapeutics Raises $300 Mi...
4P-Pharma Secures €15 Million Funding
AB-2100 Phase 1/2 Trial Initiated
Oncology Drugs Market Surge 2030
Overview
API
Cue Biopharma, a clinical-stage biopharmaceutical company, will present a corporate update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will highlight the latest developments from the company's lead clinical programs and preclinical autoimmune program.
Ask a question
How does the Immuno-STAT platform work to selectively engage and modulate disease-specific T cells?
What are the key highlights of Cue Biopharma's lead clinical programs?
What potential applications does Cue Biopharma's preclinical autoimmune program have in the field of immunology?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage